Adipotide 10mg

Researchers who buy Adipotide (FTPP) for research should evaluate the compound through RUO labeling, compound identity, COA documentation, analytical testing, and lot traceability before procurement. Adipotide, also listed as prohibitin-targeting peptide 1, is described by the NCI Drug Dictionary as a chimeric 25-mer peptide built from a CKGGRAKDC targeting motif, a GG linker, and KLAKLAK repeat motifs [1]. This guide covers laboratory research documentation. Published findings do not establish the performance of a supplier’s material.

• Adipotide (FTPP) is a research peptide whose compound identity, sequence record, and molecular-weight profile can be compared with authoritative data sources [2].
• Published adipotide research has centered on prohibitin-associated white adipose tissue vasculature models, apoptosis-related pathways, and preclinical literature interpretation [1], [3].
• Researchers should review batch-specific COA files, HPLC data, LC-MS data, lot numbers, and labeling consistency before evaluating a research material listing.
• Published adipotide studies provide model-specific scientific context, not evidence for personal use or verification of a supplier’s product.
• Analytical testing matters because HPLC and LC-MS answer different documentation questions about purity, identity, mass, and impurity characterization [16], [17].

Fast Answer: What Should Researchers Check Before They Buy Adipotide (FTPP) for Research?

Researchers evaluating where to buy Adipotide (FTPP) for research should first check RUO labeling, peptide identity, COA availability, HPLC purity documentation, LC-MS identity support, lot traceability, storage notes, and supplier records. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Adipotide’s identity should be checked against source records and batch-specific documentation [1], [2].

Adipotide identity and laboratory documentation

Laboratories evaluating where to buy Adipotide (FTPP) for research should compare compound identity, analytical records, lot traceability, and research-use-only labeling. These records identify the material being procured; they do not establish an experimental outcome.

Adipotide (FTPP) research literature covers peptide motifs, prohibitin, adipose tissue vasculature models, and apoptosis-related mechanisms [1], [3]. Those studies provide context for interpreting the compound’s research history, not verification of a purchased lot.

What Documentation Should Come First?

Start with identity documentation. The core research file should include the compound name, synonym mapping, sequence record, molecular formula, molecular weight, lot number, COA, and analytical method notes.

PubChem lists Adipotide with the sequence CKGGRAKDCGGKLAKLAKKLAKLAK, molecular formula C111H206N36O28S2, and molecular weight of about 2557.2 g/mol [2]. These identity fields help researchers compare a product listing against independent compound records.

Why RUO Labeling Matters Before Procurement?

RUO labeling identifies the material as intended for laboratory research, not consumer or clinical use.

FDA guidance for a separate but related category of research-labeled laboratory products emphasizes that RUO labeling should be consistent with research-stage intent and should not be used to support diagnostic positioning [23]. For procurement review, compare labeling with the supplier’s stated intended use.

Adipotide Research-Use-Only Context

The Adipotide material discussed here is supplied for laboratory research use only.

Published research has examined prohibitin-associated targeting motifs in white adipose tissue vasculature models [1], [3].

How Laboratory Research Use Shapes Product Documentation

The most useful records are not persuasive slogans. They are technical fields.

For Adipotide (FTPP), those fields include peptide sequence, molecular weight, purity testing method, LC-MS identity support, lot number, COA date, storage documentation, and label consistency. When these fields align, procurement teams have a clearer basis for research-material review.

Why Product Claims Stay Separate From Literature Findings?

Published literature can describe what investigators examined in a defined model. Product claims describe what a supplier says about a material being sold.

Those are different categories. Kolonin, Saha, Pasqualini, and Arap described a CKGGRAKDC motif associated with white adipose tissue vasculature and prohibitin in a preclinical model [3]. That is literature context, not a claim that any research-use-only material will reproduce the same findings.

What Is Adipotide in Research Literature?

Adipotide (FTPP) is commonly discussed as a chimeric peptide or peptidomimetic connected to prohibitin-targeting research. NCI describes prohibitin-targeting peptide 1 as a 25-mer peptide containing a CKGGRAKDC targeting motif, a GG linker, and KLAKLAK repeat motifs [1].

PubChem provides the sequence, molecular formula, molecular weight, computed descriptors, and synonym data for Adipotide [2]. Those fields support compound identity review.

Adipotide FTPP Peptide Identity and Classification

Adipotide FTPP peptide documentation should identify the compound as Adipotide, FTPP, or prohibitin-targeting peptide 1 when those synonyms are relevant. Synonym consistency helps prevent mismatched COA records, mislabeled files, or unclear catalog entries.

The NCI source describes the compound as a chimeric 25-mer peptide [1]. PubChem lists Adipotide as CID 163360068 and provides the formula and sequence fields needed for identity comparison [2].

How the Peptide Sequence Supports Compound Identification

Peptide sequence is a core identity field because it links a name to a defined primary structure. PubChem lists the Adipotide sequence as CKGGRAKDCGGKLAKLAKKLAKLAK [2].

For research procurement, sequence review should sit alongside molecular weight, mass data, and batch-specific COA documentation. A sequence alone is useful, but it does not replace analytical confirmation.

Where Prohibitin Context Fits in Adipotide Research?

Prohibitin is central to the literature context for adipotide research. The NCI description states that prohibitin-targeting peptide 1 binds prohibitin in white adipose vasculature and is associated with receptor-mediated internalization in its research description [1].

Prohibitin itself is not a narrow single-function marker. Reviews describe prohibitins as conserved proteins with roles in multiple cellular compartments, including mitochondria, membrane-associated contexts, and nuclear signaling contexts [11], [12].

Adipotide Peptide Scientific Background

Adipotide peptide literature grew out of vascular-targeting and phage-display research. In vivo phage display has been used to identify peptide motifs associated with organ- or tissue-selective vascular homing [6], [7].

That background explains why Adipotide (FTPP) is often discussed through targeting motifs, vascular endothelium, prohibitin, and apoptosis-related model interpretation. It does not create product-use guidance.

What Researchers Should Know About Prohibitin-Targeting Literature?

Prohibitin-targeting literature should be read as mechanistic research. The early Kolonin study identified the CKGGRAKDC peptide motif and reported association with prohibitin in white adipose tissue vasculature models [3].

Later research discussed prohibitin and annexin A2 interactions in adipose tissue biology. Salameh, Daquinag, Staquicini, Pasqualini, Arap, and Kolonin reported that PHB and ANX2 interact on vascular endothelial cells in white adipose tissue and discussed CD36-mediated fatty acid transport in that context [10].

How Endothelium and Vasculature Models Appear in Studies?

The endothelium matters because vascular beds are molecularly diverse. Rajotte, Arap, Pasqualini, and colleagues used phage-display methods to study molecular heterogeneity across vascular endothelium in different tissues [7].

Adipotide studies examine model-specific targeting of peptide motifs to defined vascular contexts. This is more specific than a general association with metabolism.

Why Apoptosis Is Discussed as a Mechanistic Research Topic?

Apoptosis appears in Adipotide (FTPP) research because the NCI description connects the compound’s ligand/receptor complex with apoptosis in its scientific entry [1]. Kolonin and colleagues also framed the early preclinical research around targeted induction of apoptosis in adipose tissue vasculature models [3].

These mechanistic observations do not establish the performance or suitability of a commercial RUO material.

Pathway Context for Adipotide FTPP Research

Adipotide (FTPP) pathway research includes peptide motif targeting, prohibitin, vascular endothelium, apoptosis-related model findings, and adipose tissue vasculature.

Reviews on vascular phage display explain that peptide libraries can be used to identify ligands associated with specific vascular beds [8], [9]. This provides context for the vascular-targeting methods used in Adipotide research.

How Receptor and Ligand Concepts Frame the Research Model?

In the literature, receptor and ligand language describes a model of molecular recognition. NCI describes prohibitin-targeting peptide 1 as binding specifically to prohibitin in white adipose vasculature, with receptor-mediated internalization described in the entry [1].

Researchers should treat that language as model context.

What Metabolic Pathway Models Can and Cannot Establish?

Metabolic pathway models can help researchers organize experimental findings. They cannot turn a research-use-only material into a claimed application.

For example, adipose vasculature research has shown that endothelial and vascular processes are deeply connected with adipose tissue function in model systems [14], [15]. That supports pathway context only; it does not support product claims.

Why Pathway Relevance Is Not a Product Claim?

Pathway relevance means a compound has been discussed in relation to a molecular target, cell type, or model system. It does not mean a supplier can claim a research material will produce a specific finding.

For Adipotide (FTPP), published research connects prohibitin, endothelium, vasculature, peptide identity, and apoptosis in defined study models [1], [3].

Published Literature Review for Adipotide Studies

Adipotide’s research history includes early white adipose vasculature targeting studies and later preclinical peptidomimetic research.

In vitro findings, preclinical model findings, registry records, and analytical documentation address different questions and need to be evaluated separately.

How Barnhart, Pasqualini, and Arap Anchor Early Literature

Barnhart, Christianson, Hanley, Pasqualini, Arap, and colleagues published a Science Translational Medicine study identified as 3(108):108ra112, which evaluated a peptidomimetic targeting white adipose tissue in nonhuman primate models [4]. That source is important because it extended the research context beyond the initial peptide motif work.

Pasqualini and Arap are also connected to the broader vascular-targeting research tradition. Earlier phage-display work showed that peptide motifs could be selected for tissue-associated vascular homing [6], [7].

What Science Translational Medicine Adds to Research Context?

Science Translational Medicine adds a preclinical evidence layer for adipotide research. Barnhart et al. reported a peptidomimetic research model involving white adipose tissue targeting and metabolic readouts in a nonhuman primate context [4].

This is preclinical evidence about how the compound has been studied, not verification of a supplier’s current research material.

Early Nature Medicine Research

Kolonin, Saha, Chan, Pasqualini, and Arap reported the CKGGRAKDC motif and prohibitin association in white adipose vasculature research in Nature Medicine [3].

How Should Adipotide Research Evidence Be Interpreted?

Evidence should be interpreted through a ladder: compound identity, mechanistic literature, preclinical model data, registry context, and analytical verification. Each rung supports a different kind of statement.

What Can Published Findings Establish?

Published findings can clarify compound identity, classification, and the model systems studied. They do not verify the identity or performance of a supplier’s current lot.

For Adipotide (FTPP), published sources describe CKGGRAKDC, prohibitin, peptide identity, adipose tissue vasculature models, and analytical verification [1], [2], [3], [16].

Why Study Models Require Separation From Supplier Claims?

Study models are controlled research contexts. Supplier claims are commercial statements about a research material.

For Adipotide research, model-specific literature can explain prohibitin context and vascular-targeting methodology, while supplier documentation should focus on COA review, analytical testing, label consistency, and lot traceability [3], [4], [18].

How Research Literature Stays Separate From Product Claims

Literature explains what investigators examined. Product-page documentation explains what the supplier can verify.

Key distinctions for research procurement include:

• Published literature does not verify a supplier’s current product.
• Preclinical findings are limited to the study’s models and methods.
• A purity percentage does not prove complete compound identity.
• A COA should be batch-specific.
• Pathway relevance does not equal a product claim.

For documentation review, compare identity fields, sequence records, molecular weight, supplier records, COA data, chromatograms, LC-MS identity support, and storage documentation.

Source quality also matters. Peer-reviewed studies, official databases, and recognized analytical guidance provide more reliable evidence than marketing summaries.

COA Documentation for Adipotide Peptide Review

A certificate of analysis should help researchers connect a specific lot to a specific analytical record. It should not function as decorative proof.

For Adipotide peptide review, the COA should align with the product listing, label, lot number, sequence expectations, and analytical testing files. FDA analytical-method guidance describes identity, quality, purity, and related attributes as documentation areas supported by analytical procedures and validation data in regulated analytical contexts [18].

Why Certificate of Analysis Details Matter?

COA details matter because they turn broad quality language into checkable fields. A useful COA should state the compound name, lot number, test date, purity method, identity method, and lab source.

Researchers should also compare COA data against independent identity fields. For Adipotide (FTPP), molecular-weight and sequence expectations can be compared with PubChem and NCI records [1], [2].

What Batch-Specific Documentation Should Show?

Batch-specific documentation should show that the listed material and the tested material refer to the same lot. The lot number on the COA should match the product documentation, label record, and procurement record.

A COA for a peptide should not be evaluated from a headline purity number alone. Analytical literature explains that mass spectrometry and LC-MS can support synthetic peptide identity and purity review when paired with suitable method context [16], [17].

Analytical Testing for Adipotide (FTPP) Peptide Identity

Analytical testing supports research-material documentation. HPLC and LC-MS answer related but different questions.

Use this lab-test verification sequence for documentation review:

1. Verify that the compound name, synonym, lot number, and label match across records.
2. Review the batch-specific COA.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS, MS, or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Document storage and handling requirements in the laboratory record.

How HPLC Supports Peptide Purity Review?

HPLC is commonly used to separate components in a sample and support purity review. It can show retention-time behavior, peak area context, and whether a dominant peak appears under the stated method conditions.

HPLC should not be read as a complete identity answer by itself. For synthetic peptides, mass spectrometry is well suited for identity and purity analysis, and LC-MS is often used as part of peptide characterization [16], [17].

How LC-MS Supports Identity Verification?

LC-MS combines separation with mass analysis, which makes it useful for synthetic peptide identity review and impurity characterization. Lian and colleagues describe LC-MS as important for synthetic peptide characterization because peptides can contain complex structural modifications linked to starting materials, manufacturing processes, and storage conditions [17].

For Adipotide (FTPP), LC-MS documentation should be compared with expected mass and sequence information from compound records [2]. When available, it should be reviewed alongside COA and lot data rather than in isolation.

Lot Traceability and Labeling Documentation

Lot traceability helps connect the material, label, COA, and testing files. It is one of the simplest ways to detect mismatches across product documentation.

A research buyer should be able to follow a clear path from product name to lot number, then from lot number to COA, and from COA to analytical files. If the path breaks, documentation review becomes weaker.

What Do Lot Numbers Add to Procurement Review?

Lot numbers add specificity. They help distinguish a batch-specific COA from a general quality statement.

Analytical guidance emphasizes that method validation and analytical data support defined quality attributes in documented contexts [18], [19]. For research procurement, that principle translates into a practical question: does the lot-level record support the exact material being evaluated?

How Traceability Supports Laboratory Records

Traceability supports laboratory records by making each research material auditable. The product listing, COA, label, storage note, and internal receiving record should align.

This is not just paperwork. It protects the integrity of laboratory documentation and helps researchers avoid ambiguity when comparing materials across suppliers or batches.

Supplier Documentation for Adipotide Research

Supplier documentation should make the Adipotide research material easy to evaluate without relying on promotional language. The strongest supplier records are specific, consistent, and tied to the batch.

A documentation matrix can help:

• Verify RUO labeling on the product listing and label.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are linked to an analytical method.
• Check that the lot number matches across files.
• Compare compound name, sequence, and molecular weight against independent records.
• Assess whether the product page avoids consumer-facing claims.
• Document storage and handling conditions in a laboratory record.

Why Supplier Records Should Match Product Listing Details?

Supplier records should match product listing details because mismatch creates uncertainty. A listing that says Adipotide (FTPP), a COA that uses a different synonym, and a label with unclear lot data require extra review.

Synonyms can be acceptable when they are clearly mapped. PubChem and NCI records help researchers connect Adipotide, FTPP, and prohibitin-targeting peptide 1 as research identifiers [1], [2].

How Research-Use Labeling Clarifies Intended Use

Research-use labeling identifies the material as intended for laboratory research, not consumer use.

FDA RUO guidance for research-labeled laboratory products warns that labeling and distribution should be consistent with research intent rather than diagnostic positioning [23].

Storage and Handling Documentation for Laboratory Research

Storage and handling documentation should state the supplier’s storage conditions and help laboratory teams record receipt, storage location, date, and lot number.

Peptides and polypeptides can be sensitive to environmental factors such as temperature changes, oxidation, light, ionic content, and shear, according to ICH Q5C stability guidance for biotechnological and biological products [21]. Solid-state peptide stability also remains a documented concern in pharmaceutical chemistry literature [22].

What Should Researchers Check in Storage Notes?

The storage note should be consistent across the listing, COA, label, and any supplier documentation.

How Handling Records Support Research Material Integrity

Handling records support material integrity by creating a chain of custody. That record may include receipt date, lot number, storage location, COA file name, reviewer initials, and any internal documentation notes.

For research teams, the most practical standard is consistency. If the product listing, label, COA, and internal record say the same thing, review is simpler.

Research Procurement Review for Adipotide Peptide

Adipotide (FTPP) procurement review brings together compound identity, literature context, analytical testing, COA records, supplier documentation, and RUO labeling.

Before procurement, researchers should check whether the product page gives enough information to support an internal review. The strongest pages make the documentation path visible.

What Researchers Should Verify Before They Buy Adipotide for Research?

Researchers evaluating where to buy Adipotide for research should verify RUO labeling, compound identity, synonym consistency, sequence expectations, molecular weight, COA availability, HPLC documentation, LC-MS identity support, lot traceability, storage notes, and supplier documentation.

Researchers should distinguish published study findings from supplier assertions and check which records support the actual material being evaluated.

How Documentation Review Supports Next-Step Evaluation

Documentation review supports next-step evaluation by reducing ambiguity before a research material is selected.

“Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.”

Review the product-page documentation, COA details, analytical testing files, and RUO labeling before evaluating Adipotide (FTPP) for laboratory research.

FAQs

What is Adipotide (FTPP) in research context?

Adipotide (FTPP) is described in research context as a peptide-related research compound associated with prohibitin-targeting literature and compound identity review. Researchers may compare synonym records, amino acid information, molecular weight, and COA details when evaluating Adipotide documentation [1], [2].

What should researchers consider before they buy Adipotide (FTPP) for research?

Researchers should consider documentation before they buy Adipotide (FTPP) for research. A research-focused review should include RUO labeling, supplier documentation, peptide COA availability, lot traceability, analytical testing, storage documentation, and consistency across product records. The goal is to evaluate research-material documentation, not to interpret the compound through consumer-facing product claims.

How should Adipotide research materials be stored?

Adipotide research materials should be stored according to the supplier’s laboratory storage documentation and internal research records.

Why do researchers review peptide COA documentation for Adipotide?

Researchers review peptide COA documentation for Adipotide because it helps connect the listed research material to a batch-specific record. A useful COA supports review of lot number, purity method, identity testing, test date, and supplier documentation. COA review works best when paired with analytical testing records and clear lot traceability.

How does pathway research help frame Adipotide literature?

Pathway research helps frame Adipotide literature by placing published findings into model-specific scientific context. Researchers may encounter terms such as receptor signaling, cell signaling, signal transduction, molecular binding, cell membrane, or endocytosis in related literature.

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Mikhail G. Kolonin, PhD

Author profile: Gulf Coast Consortia Faculty Profile

Mikhail G. Kolonin’s publications provide background on white adipose tissue vasculature models, prohibitin-associated research, and peptide motif selection. His later work with annexin 2 and prohibitin examines molecular interactions in adipose tissue biology.

Selected publications:

• A peer-reviewed study on white adipose tissue vasculature targeting — Nature Medicine, 2004. DOI: 10.1038/nm1048. PMID: [15133506]
• Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue — JCI Insight, 2016. DOI: 10.1172/jci.insight.86351

Renata Pasqualini, PhD

Author profile: Rutgers PI Profile

Renata Pasqualini’s publications are relevant to the vascular-targeting and phage-display research background that informs the Adipotide (FTPP) literature context. Her work helps frame how peptide libraries, endothelial markers, and tissue-associated vascular signatures appear in published research.

Selected publications:

• A peer-reviewed study on phage-display peptide library targeting — Nature, 1996. DOI: 10.1038/380364a0. PMID: [8598934]
• A peer-reviewed study on vascular endothelium heterogeneity and phage display — Journal of Clinical Investigation, 1998. DOI: 10.1172/JCI3008. PMID: [9664085]

REFERENCES

1. National Cancer Institute. Prohibitin-targeting peptide 1 definition. NCI Drug Dictionary. Accessed 2026.
2. PubChem. Adipotide compound record. National Center for Biotechnology Information, PubChem CID 163360068. Accessed 2026.
3. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. White adipose vasculature targeting study. Nature Medicine. 2004. PMID: 15133506. DOI: 10.1038/nm1048.
4. Barnhart KF, Christianson DR, Hanley PW, Driessen WHP, Bernacky BJ, Baze WB, et al. Preclinical peptidomimetic study in white adipose tissue models. Science Translational Medicine. 2011;3(108):108ra112. PMID: 22072637. PMCID: PMC3666164. DOI: 10.1126/scitranslmed.3002621.
5. ClinicalTrials.gov. Prohibitin-targeting peptide 1 registry record. U.S. National Library of Medicine. ClinicalTrials.gov ID: NCT01262664. Last update posted 2019.
6. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996. PMID: 8598934. DOI: 10.1038/380364a0.
7. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. Journal of Clinical Investigation. 1998. PMID: 9664085. PMCID: PMC508902. DOI: 10.1172/JCI3008.
8. Bábíčková J, Tóthová Ľ, Boor P, Celec P. In vivo phage display as a discovery tool in molecular biomedicine. Biotechnology Advances. 2013. PMID: 23623852. DOI: 10.1016/j.biotechadv.2013.04.004.
9. Pasqualini R. Vascular targeting with phage peptide libraries. Quarterly Journal of Nuclear Medicine. 1999. PMID: 10429511.
10. Salameh A, Daquinag AC, Staquicini DI, An Z, Hajjar KA, Pasqualini R, Arap W, Kolonin MG. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016;1(10):e86351. DOI: 10.1172/jci.insight.86351.
11. Mishra S, Murphy LC, Murphy LJ. The Prohibitins: emerging roles in diverse functions. Journal of Cellular and Molecular Medicine. 2006. PMID: 16796804. DOI: 10.1111/j.1582-4934.2006.tb00404.x.
12. Signorile A, Sgaramella G, Bellomo F, et al. Prohibitins in mitochondrial function research. Cells. 2019. DOI: 10.3390/cells8010071.
13. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. International Journal of Molecular Sciences. 2013. PMID: 23519104. PMCID: PMC3634455. DOI: 10.3390/ijms14036259.
14. Herold J, Kalucka J. Angiogenesis in adipose tissue: interplay between adipose and endothelial cells. Frontiers in Physiology. 2021. DOI: 10.3389/fphys.2020.624903.
15. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, et al. Adipose VEGF and vascular remodeling in metabolic pathway models. Cell Metabolism. 2013. PMID: 23312284. DOI: 10.1016/j.cmet.2012.12.010.
16. Prabhala BK, Mirza O, Højrup P, Hansen PR. Characterization of synthetic peptides by mass spectrometry. Methods in Molecular Biology. 2015. PMID: 26424265. DOI: 10.1007/978-1-4939-2999-3_9.
17. Lian Z, Wang N, Tian Y, Huang L. Characterization of synthetic peptides using liquid chromatography–mass spectrometry. Journal of the American Society for Mass Spectrometry. 2021. PMID: 34110145. DOI: 10.1021/jasms.0c00479.
18. U.S. Food and Drug Administration. Analytical procedures and methods validation guidance. FDA Guidance Document. 2015.
19. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA / ICH Guidance Document. 2024.
20. European Medicines Agency. ICH Q2(R2) validation of analytical procedures scientific guideline. EMA Scientific Guideline. 2024.
21. U.S. Food and Drug Administration. Q5C stability testing guidance for biotechnological and biological products. FDA / ICH Guidance Document. 1996.
22. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. Journal of Pharmaceutical Sciences. 1999. PMID: 10229638. DOI: 10.1021/js980374e.
23. U.S. Food and Drug Administration. Distribution of laboratory products labeled for research use only or investigational use only. FDA Guidance Document. 2013.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.